These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27409565)

  • 21. Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?
    Esteve-Pastor MA; García-Fernández A; Macías M; Sogorb F; Valdés M; Roldán V; Muñiz J; Badimon L; Roldán I; Bertomeu-Martínez V; Cequier Á; Lip GY; Anguita M; Marín F;
    Circ J; 2016 Sep; 80(10):2102-8. PubMed ID: 27557850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
    Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.
    Roldán V; Marín F; Fernández H; Manzano-Fernandez S; Gallego P; Valdés M; Vicente V; Lip GYH
    Chest; 2013 Jan; 143(1):179-184. PubMed ID: 22722228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Sanmartin Fernández M; Arribas F; Masjuan J; Barrios V; Cosin-Sales J; Freixa-Pamias R; Recalde E; Pérez-Cabeza AI; Manuel Vázquez Rodríguez J; Ràfols Priu C; Anguita Sánchez M; Lip GYH; Marin F
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):38-46. PubMed ID: 36318457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding risk in patients with atrial fibrillation: the AMADEUS study.
    Lane DA; Kamphuisen PW; Minini P; Büller HR; Lip GYH
    Chest; 2011 Jul; 140(1):146-155. PubMed ID: 21415134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
    Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
    Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
    Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants.
    Wattanaruengchai P; Nathisuwan S; Karaketklang K; Wongcharoen W; Phrommintikul A; Lip GYH
    Br J Clin Pharmacol; 2022 May; 88(5):2203-2212. PubMed ID: 34783372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
    Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry.
    Proietti M; Romiti GF; Vitolo M; Potpara TS; Boriani G; Lip GYH
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):778-786. PubMed ID: 34555148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Zhu W; He W; Guo L; Wang X; Hong K
    Clin Cardiol; 2015 Sep; 38(9):555-61. PubMed ID: 26418409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.
    Senoo K; Lip GY
    Stroke; 2015 Nov; 46(11):3202-7. PubMed ID: 26463692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Gao X; Cai X; Yang Y; Zhou Y; Zhu W
    Front Cardiovasc Med; 2021; 8():757087. PubMed ID: 34881309
    [No Abstract]   [Full Text] [Related]  

  • 35. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.
    Lip GY; Banerjee A; Lagrenade I; Lane DA; Taillandier S; Fauchier L
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):941-8. PubMed ID: 22923275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Guo Y; Lane DA; Buller H; Lip GY
    Eur Heart J; 2013 Dec; 34(46):3572-9. PubMed ID: 23966309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: A PRISMA-compliant article.
    Zeng J; Yu P; Cui W; Wang X; Ma J; Zeng C
    Medicine (Baltimore); 2020 Jun; 99(25):e20782. PubMed ID: 32569222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA
    Denas G; Zoppellaro G; Padayattil Jose S; Antonucci E; Marongiu F; Poli D; Testa S; Tripodi A; Palareti G; Pengo V
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation.
    Guo Y; Zhu H; Chen Y; Lip GYH
    Am J Med; 2018 Feb; 131(2):185-192. PubMed ID: 28943382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.